James  Hippel net worth and biography

James Hippel Biography and Net Worth

CFO of Bio-Techne
James T. Hippel became Chief Financial Officer on April 1, 2014. Prior to joining the Company, he served as Senior Vice President and CFO for Mirion Technologies, Inc., a $300 million global technology and manufacturing company which provides mission critical products to detect, monitor and identify radiation. Prior to Mirion, Mr. Hippel served as Vice President, Finance at Thermo Fisher Scientific, Inc., leading finance operations for its $2 billion Mass Spectrometry & Chromatography and $1 billion Laboratory Consumables divisions. Mr. Hippel's experience also includes nine years of progressive financial leadership at Honeywell International, within its Aerospace Segment. He began his career with KPMG Peat Marwick LLP. 

Mr. Hippel holds a Master of Business Administration from Arizona State University and a Bachelor of Accountancy degree from Northern Arizona University. He is also a CPA (inactive).

What is James Hippel's net worth?

The estimated net worth of James Hippel is at least $888,669.60 as of August 9th, 2021. Mr. Hippel owns 12,520 shares of Bio-Techne stock worth more than $888,670 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Hippel may own. Additionally, Mr. Hippel receives an annual salary of $691,780.00 as CFO at Bio-Techne. Learn More about James Hippel's net worth.

How old is James Hippel?

Mr. Hippel is currently 53 years old. There are 5 older executives and no younger executives at Bio-Techne. The oldest executive at Bio-Techne is Mr. Charles R. Kummeth, Senior Advisor & Director, who is 64 years old. Learn More on James Hippel's age.

What is James Hippel's salary?

As the CFO of Bio-Techne Co., Mr. Hippel earns $691,780.00 per year. There are 3 executives that earn more than Mr. Hippel. The highest earning executive at Bio-Techne is Mr. Charles R. Kummeth, Senior Advisor & Director, who commands a salary of $1,260,000.00 per year. Learn More on James Hippel's salary.

How do I contact James Hippel?

The corporate mailing address for Mr. Hippel and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on James Hippel's contact information.

Has James Hippel been buying or selling shares of Bio-Techne?

James Hippel has not been actively trading shares of Bio-Techne during the last quarter. Most recently, James Hippel sold 662 shares of the business's stock in a transaction on Friday, October 29th. The shares were sold at an average price of $525.23, for a transaction totalling $347,702.26. Learn More on James Hippel's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (CEO, President & Director), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 10,400 shares worth more than $800,592.00. The most recent insider tranaction occured on March, 7th when Director Roeland Nusse sold 10,400 shares worth more than $800,592.00. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 3/7/2024.

James Hippel Insider Trading History at Bio-Techne

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/29/2021Sell662$525.23$347,702.26View SEC Filing Icon  
9/2/2021Sell10,000$507.22$5,072,200.00View SEC Filing Icon  
8/9/2021Sell10,000$478.90$4,789,000.0012,520View SEC Filing Icon  
7/12/2021Sell10,000$456.67$4,566,700.00View SEC Filing Icon  
6/7/2021Sell9,942$421.93$4,194,828.0619,079View SEC Filing Icon  
1/11/2021Sell10,000$333.63$3,336,300.0019,137View SEC Filing Icon  
11/11/2020Sell7,391$307.05$2,269,406.5512,737View SEC Filing Icon  
11/9/2020Sell3,600$309.79$1,115,244.0012,737View SEC Filing Icon  
11/5/2020Sell8,809$286.12$2,520,431.0816,237View SEC Filing Icon  
7/7/2020Sell2,577$271.43$699,475.1130,809View SEC Filing Icon  
11/21/2019Sell11,349$215.36$2,444,120.6420,656View SEC Filing Icon  
5/1/2019Sell35,000$203.08$7,107,800.00View SEC Filing Icon  
See Full Table

James Hippel Buying and Selling Activity at Bio-Techne

This chart shows James Hippel's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $70.98
Low: $68.42
High: $71.18

50 Day Range

MA: $73.88
Low: $66.37
High: $80.36

2 Week Range

Now: $70.98
Low: $61.16
High: $85.57

Volume

743,722 shs

Average Volume

1,027,162 shs

Market Capitalization

$11.28 billion

P/E Ratio

75.51

Dividend Yield

0.48%

Beta

1.28